Skip to content

Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder

Cognitive Affective Behavior Therapy for Somatization

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00149760
Enrollment
88
Registered
2005-09-08
Start date
2003-08-31
Completion date
2010-02-28
Last updated
2014-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Somatization Disorder

Keywords

Cognitive Behavior Therapy, Treatment Outcome, Health Care Utilization, Somatization Disorder, Somatoform Disorder

Brief summary

This study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder.

Detailed description

Somatization disorder is a syndrome characterized by the presence of multiple medically unexplained physical symptoms. It often results in substantial functional impairment and the need for extensive medical treatment. Neither pharmacological nor psychosocial treatments for the disease have demonstrated clinical success. People with somatization disorder may benefit from a treatment that integrates emotion-centered strategies into cognitive behavioral therapy. The long-term effectiveness of this treatment has not been established, however. This study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder. Participants in this open-label study will be randomly assigned to receive either cognitive-affective behavior therapy (CABT) or standard medical care that is augmented by a psychiatric consultation. Treatment will last 4 months. Assessments of somatic symptomatology, functional impairment, and health care costs will occur at screening, baseline (1 to 2 weeks after screening), and 4, 10, and 16 months after baseline. The visits at 10 and 16 months post-baseline will assess specifically the long-term efficacy of the treatment.

Interventions

BEHAVIORALAugmented Standard Medical Care

Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.

BEHAVIORALCognitive-Affective Behavior Therapy

Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Meets DSM-IV criteria for somatization disorder * Available for follow-up over the ensuing 18 months * English-speaking

Exclusion criteria

* Meets DSM-IV criteria for a psychotic disorder, organic brain syndrome, or psychoactive substance dependence (Other psychiatric comorbidity is not exclusionary) * Active suicidal ideation * Unstable major medical condition * Plans to engage in additional psychotherapy during the first 6 months after enrollment * Current use of any medication that has not been stabilized for the previous 2 months

Design outcomes

Primary

MeasureTime frame
Clinical Global Impression Scale for Somatization DisorderMeasured at baseline and Months 4, 10, and 16

Secondary

MeasureTime frame
Physical functioningMeasured at baseline and Months 4, 10, and 16
Health care utilizationMeasured between Months 4 and 16

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026